Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ocular lens crystallin proteins are the primary structural components of the vertebrate eye lens, constituting up to 90% of its water-soluble protein content [1]. They are categorized into three main families: alpha, beta, and gamma crystallins, which are organized in a high-density gradient to maintain lens transparency and refractive power [2]. Alpha-crystallins, in particular, function as small heat-shock proteins (sHSPs) that act as molecular chaperones to prevent the irreversible aggregation of denatured proteins [3]. Since the lens does not undergo protein turnover, these proteins are susceptible to lifelong accumulation of oxidative damage and post-translational modifications [4]. This damage eventually leads to protein misfolding and the formation of large, light-scattering aggregates, resulting in cataracts, the leading cause of blindness worldwide [5]. Pharmacological interventions, such as lanosterol and chaperone-mimetic compounds, are being investigated for their ability to stabilize crystallins or dissolve existing aggregates to restore lens clarity [6, 7]. Sources: [1] Slingsby et al. (2013) Exp Eye Res; [2] Hejtmancik et al. (2015) Prog Retin Eye Res; [3] Horwitz (1992) PNAS; [4] Truscott (2005) Exp Eye Res; [5] Zhao et al. (2015) Nature; [6] Makley et al. (2015) Science; [7] Molnar et al. (2019) Exp Eye Res.
Small-molecule binding to crystallin proteins to stabilize their native fold and prevent or reverse the formation of light-scattering amyloid-like aggregates, thereby restoring lens clarity [5, 6].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular lens crystallin protein (Crystallin).